Latest News

View All
Dec 04, 2018

Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology

Read More
Dec 03, 2018

Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting

Read More
Nov 28, 2018

Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

Read More
Nov 01, 2018

Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting

Read More
Oct 26, 2018

Gamida Cell Announces Pricing of Initial Public Offering

Read More
Sep 18, 2018

Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman

Read More
Aug 06, 2018

Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications

Read More
Jul 23, 2018

Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access

Read More
Jul 17, 2018

Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation

Read More
Jun 18, 2018

Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma

Read More
Apr 30, 2018

Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting

Read More
Apr 26, 2018

Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing

Read More
Mar 19, 2018

Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting

Read More
Mar 16, 2018

Gamida Cell to Present at Upcoming Investor Conferences

Read More
Mar 15, 2018

Gamida Cell Appoints Shai Lankry as Chief Financial Officer

Read More
Feb 20, 2018

Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings

Read More
Jan 16, 2018

Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma

Read More
Dec 11, 2017

Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

Read More
Nov 20, 2017

Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer

Read More
Nov 01, 2017

Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting

Read More
Sep 26, 2017

Gamida Cell World Cord Blood Day Conference, November 15, 2017

Read More
Aug 21, 2017

Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS

Read More
Jul 10, 2017

Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer

Read More
Jun 19, 2017

Gamida Cell Announces $40 Million Private Financing

Read More
Jun 05, 2017

Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg and Immune Oncology Expert Dr. Michael Perry to its Board of Directors

Read More
Apr 20, 2017

Gamida Cell Announces Publication of Positive Clinical Outcomes from NiCord-Transplanted Patients in the Journal of Biology of Blood and Marrow Transplantation

Read More
Mar 23, 2017

Gamida Cell Receives Additional EMA Orphan Drug Designation for NiCord® in Haematopoietic Stem Cell Transplantation (HSCT)

Read More
Feb 28, 2017

Gamida Cell Announces First Patient Transplanted in Phase 3 Registration Study of NiCord for Blood Cancers

Read More
Dec 06, 2016

Gamida Cell Presents Positive Data From Phase 1/2 Study of NiCord® as a Curative Treatment for Sickle Cell Disease at ASH 2016

Read More
Nov 21, 2016

Gamida Cell Names Julian Adams, Ph.D. New Chairman of the Board

Read More
Oct 11, 2016

Gamida Cell Receives FDA Breakthrough Therapy Designation For NiCord®

Read More
Sep 15, 2016

Gamida Cell Announces Appointment of Julian Adams, Ph.D.and Kenneth I. Moch to its Board of Directors

Read More
Jul 27, 2016

Gamida Cell Announces First Patient with Sickle Cell Disease Transplanted in Phase 1/2 Study of CordIn™ as the Sole Graft Source

Read More
Jun 06, 2016

Gamida Cell Presents Data From Phase 1/2 Study of NiCord® for High Risk Hematological Malignancies at ASCO 2016

Read More
May 23, 2016

Gamida Cell Announces $4.4 Million Grant from the Israeli Government

Read More
Apr 05, 2016

Gamida Cell Presents Additional Positive Data of NiCord® in Blood Cancer Patients at EBMT 2016

Read More

Committed to changing treatment paradigms

We are focused on developing novel cell therapies as a potentially curative approach for patients with serious medical conditions who have limited treatment options.

Learn more about the cell therapies we are developing.